Halting Neurodegeneration with
Disease Altering Therapeutics

Welcome to AcureX Therapeutics

AcureX's mission is to halt neurodegenerative diseases starting with Parkinson’s Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinson’s in human trials in 2023, followed by candidates for other neurodegenerative diseases.


AcureX’s approach and founding intellectual property are based on discoveries made by the company’s inventor co-founder, Xinnan Wang MD, Ph.D. Using these insights, AcureX has built a Miro1 Mitophagy Discovery Platform to accelerate drug development. AcureX's therapeutics apply to LRRK2-G2019S, SNCA-A53T, and GBA-N370S as well as sporadic forms of Parkinson's disease. Additionally, AcureX is developing a Parkinson's biomarker to understand Mitophagy Profiles in PD and de-risk clinical trials through patient stratification and target engagement insights.


The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs.

Supported by $5.5M from the Michael J. Fox Foundation for Parkinson’s Research, the Silverstein Foundation for Parkinson's with GBA, NIH grant funding and private funding.